PTPRS

Summary

PTPRS (protein tyrosine phosphatase receptor type S, HGNC:9681) is a protein-coding gene on chromosome 19p13.3, encoding Receptor-type tyrosine-protein phosphatase S (Q13332). Cell surface receptor that binds to glycosaminoglycans, including chondroitin sulfate proteoglycans and heparan sulfate proteoglycan.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular region, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. The extracellular region of this protein is composed of multiple Ig-like and fibronectin type III-like domains. Studies of the similar gene in mice suggested that this PTP may be involved in cell-cell interaction, primary axonogenesis, and axon guidance during embryogenesis. This PTP has been also implicated in the molecular control of adult nerve repair. Four alternatively spliced transcript variants, which encode distinct proteins, have been reported.

Source: NCBI Gene 5802 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 463 total — 1 likely-pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_002850

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9681
Approved symbol	PTPRS
Name	protein tyrosine phosphatase receptor type S
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	PTPsigma, PTP-sigma
Ensembl gene	ENSG00000105426
Ensembl biotype	protein_coding
OMIM	601576
Entrez	5802

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 8 protein_coding, 4 protein_coding_CDS_not_defined, 4 retained_intron

ENST00000262963, ENST00000586065, ENST00000587303, ENST00000588012, ENST00000588552, ENST00000589851, ENST00000590509, ENST00000591760, ENST00000592099, ENST00000706768, ENST00000706769, ENST00000706770, ENST00000706771, ENST00000850941, ENST00000919618, ENST00000919619

RefSeq mRNA: 7 — MANE Select: NM_002850 NM_001394011, NM_001394012, NM_001394013, NM_002850, NM_130853, NM_130854, NM_130855

CCDS: CCDS12139, CCDS12140, CCDS45930

Canonical transcript exons

ENST00000262963 — 38 exons

Exon	Start	End
ENSE00000665627	5225727	5225844
ENSE00000665628	5229316	5229342
ENSE00001161186	5222689	5223297
ENSE00001161200	5229491	5229684
ENSE00001161206	5231310	5231615
ENSE00001682198	5260805	5260822
ENSE00001712401	5262964	5262972
ENSE00003471801	5216720	5216767
ENSE00003565105	5286050	5286234
ENSE00003801317	5212337	5212491
ENSE00003801725	5210679	5210805
ENSE00003802713	5221000	5221253
ENSE00003802909	5256108	5256119
ENSE00003803476	5265008	5265196
ENSE00003803489	5211965	5212250
ENSE00003803744	5219939	5220154
ENSE00003803870	5211590	5211768
ENSE00003804105	5214561	5214736
ENSE00003804565	5207922	5208057
ENSE00003805416	5208237	5208391
ENSE00003805459	5210469	5210594
ENSE00003805613	5273442	5273583
ENSE00003805942	5219310	5219467
ENSE00003806110	5215498	5215595
ENSE00003806224	5240199	5240332
ENSE00003806927	5218420	5218532
ENSE00003808683	5222123	5222220
ENSE00003808849	5238919	5239063
ENSE00003808850	5218787	5218798
ENSE00003809137	5220260	5220353
ENSE00003809289	5215289	5215412
ENSE00003809409	5274199	5274344
ENSE00003809429	5214361	5214480
ENSE00003810425	5258017	5258127
ENSE00003936191	5340664	5340812
ENSE00004282831	5243901	5244482
ENSE00004282832	5245776	5246045
ENSE00004282833	5205508	5206842

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 98.47.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 57.1795 / max 780.9923, expressed in 1596 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
178535	31.9920	1568
178540	22.9471	1429
178536	1.1839	692
178534	0.3526	162
178541	0.3479	209
178515	0.1902	73
178533	0.1659	57

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.47	gold quality
ganglionic eminence	UBERON:0004023	98.45	gold quality
sural nerve	UBERON:0015488	97.27	gold quality
ventricular zone	UBERON:0003053	97.15	gold quality
tibial nerve	UBERON:0001323	95.08	gold quality
mucosa of stomach	UBERON:0001199	94.45	gold quality
stromal cell of endometrium	CL:0002255	93.58	gold quality
left uterine tube	UBERON:0001303	93.44	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.25	gold quality
right ovary	UBERON:0002118	93.06	gold quality
right coronary artery	UBERON:0001625	92.90	gold quality
right lung	UBERON:0002167	92.90	gold quality
frontal pole	UBERON:0002795	92.81	silver quality
right atrium auricular region	UBERON:0006631	92.77	gold quality
endocervix	UBERON:0000458	92.63	gold quality
left ovary	UBERON:0002119	92.28	gold quality
paraflocculus	UBERON:0005351	92.05	silver quality
calcaneal tendon	UBERON:0003701	92.00	gold quality
cerebellar hemisphere	UBERON:0002245	91.92	gold quality
omental fat pad	UBERON:0010414	91.89	gold quality
right uterine tube	UBERON:0001302	91.80	gold quality
cerebellar cortex	UBERON:0002129	91.76	gold quality
peritoneum	UBERON:0002358	91.75	gold quality
ectocervix	UBERON:0012249	91.67	gold quality
left coronary artery	UBERON:0001626	91.65	gold quality
body of uterus	UBERON:0009853	91.63	gold quality
middle frontal gyrus	UBERON:0002702	91.59	silver quality
right lobe of thyroid gland	UBERON:0001119	91.40	gold quality
prefrontal cortex	UBERON:0000451	91.12	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	91.11	gold quality

Single-cell (SCXA)

Detected in 21 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-MTAB-8498	yes	2949.93
E-MTAB-7051	yes	1290.74
E-GEOD-81608	yes	831.28
E-HCAD-5	yes	759.68
E-HCAD-4	yes	412.48
E-GEOD-149689	yes	361.96
E-CURD-11	yes	265.51
E-MTAB-10018	yes	248.05
E-GEOD-135922	yes	47.97
E-MTAB-9067	yes	17.91
E-ANND-3	yes	15.71
E-CURD-122	yes	15.05
E-MTAB-9467	yes	12.89
E-MTAB-9801	yes	8.09
E-MTAB-6678	yes	6.08

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 24)

• interactions between RPTP-domain1s and RPTP-domain 2s are a common but specific mechanism that is likely to be regulated- domain2s and the wedge structures are crucial determinants of binding specificity, thus regulating cross-talk between RPTPs (PMID:12376545)
• Transient overexpression of the short splice variant 3 of RPTPR Sigma conferred alpha-LTX induced secretion to hamster insulinoma (HIT-15) cells. In contrast, the long splice variant 2 was inactive in secretion or in a single cell assay. (PMID:16552719)
• Three SNPs that flank exon 8 are associated with ulcerative colitis. The presence of these SNPs is associated with novel splicing that removes the third immunoglobulin-like domain (exon 9) from the extracellular portion of PTPsigma. (PMID:17614280)
• SNPs rs1143699, rs4807015, and rs1978237 confer an increased risk of developing type 2 diabetes mellitus. (PMID:17893260)
• In colorectal tumors, microsatellite repeats mutation rates are higher than the mean mutation frequency (PMID:19000305)
• Trans-synaptic adhesions between netrin-G ligand-3 (NGL-3) and receptor tyrosine phosphatases LAR, protein-tyrosine phosphatase delta (PTPdelta), and PTPsigma via specific domains regulate excitatory synapse formation. (PMID:20139422)
• The receptor protein tyrosine phosphatase sigma (RPTPsigma) has now been identified as a receptor for inhibitory chondroitin sulfate proteoglycans. (PMID:20179269)
• Data show that PTPsigma localizes to PtdIns3P-positive membranes in cells, and this vesicular localization is enhanced during autophagy. (PMID:21303930)
• crystallographic analyses of a shared HSPG-CSPG binding site reveal a conformational plasticity that can accommodate diverse glycosaminoglycans with comparable affinities; HS and analogs induced RPTPsigma ectodomain oligomerization which was inhibited by CS (PMID:21454754)
• Transgenic zebrafish carrying a promoter-driven expression vector reveal the increased density of olfactory sensory neuron-specific cell synapses. (PMID:21812780)
• Structural insights into the homology and differences between mouse protein tyrosine phosphatase-sigma and human protein tyrosine phosphatase-sigma. (PMID:22027896)
• Intragenic microdeletions of the EGFR phosphatase PTPRS were found frequently (26%) in head and neck cancers, identifying this gene as a target of 19p13 loss. (PMID:22065749)
• Receptor protein tyrosine phosphatase sigma (RPTPsigma) regulates neuronal extension and acts as a presynaptic nexus for multiple protein and proteoglycan interactions during synaptogenesis. (PMID:25385546)
• Data demonstrate that synoviocytes are regulated by an RPTPsigma-dependent proteoglycan switch in vivo, which can be targeted for rheumatoid arthritis therapy. (PMID:25995222)
• represents an evolutionarily conserved pDC-specific inhibitory receptor, and is required to prevent spontaneous IFN production and immune-mediated intestinal inflammation (PMID:26231120)
• Study identified several CpG sites and specifically several CpGs in the PTPRS and PER3 genes differentially methylated between obese and non-obese children, suggesting a role for DNA methylation concerning development of childhood obesity. (PMID:28614626)
• interaction of receptor type of protein tyrosine phosphatase sigma (RPTPsigma) with a glycosaminoglycan library (PMID:29420785)
• loss of PTPRS expression may predict an aggressive clinical course in ESCC patients. PTPRS may function as a tumor suppressor and play an important role in esophageal squamous cell carcinoma growth and metastasis (PMID:29745967)
• PTPRS modulates ERK phosphorylation and subsequent translocation to the nucleus. (PMID:29915291)
• High PTPRS expression is associated with hepatocellular carcinoma progression. (PMID:31417183)
• Identification of PTPRsigma-interacting proteins by proximity-labelling assay. (PMID:33313879)
• High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. (PMID:35991009)
• PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer’s disease. (PMID:38926456)
• Reduced PTPRS expression promotes epithelial-mesenchymal transition of Schwann cells in NF1-related plexiform neurofibromas. (PMID:39094827)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ptprs	ENSMUSG00000013236
rattus_norvegicus	Ptprs	ENSRNOG00000047247

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Receptor-type tyrosine-protein phosphatase S — Q13332 (reviewed: Q13332)

Alternative names: Receptor-type tyrosine-protein phosphatase sigma

All UniProt accessions (3): Q13332, G8JL96, Q8NHS7

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface receptor that binds to glycosaminoglycans, including chondroitin sulfate proteoglycans and heparan sulfate proteoglycan. Binding to chondroitin sulfate and heparan sulfate proteoglycans has opposite effects on PTPRS oligomerization and regulation of neurite outgrowth. Contributes to the inhibition of neurite and axonal outgrowth by chondroitin sulfate proteoglycans, also after nerve transection. Plays a role in stimulating neurite outgrowth in response to the heparan sulfate proteoglycan GPC2. Required for normal brain development, especially for normal development of the pituitary gland and the olfactory bulb. Functions as a tyrosine phosphatase. Mediates dephosphorylation of NTRK1, NTRK2 and NTRK3. Plays a role in down-regulation of signaling cascades that lead to the activation of Akt and MAP kinases. Down-regulates TLR9-mediated activation of NF-kappa-B, as well as production of TNF, interferon alpha and interferon beta.

Subunit / interactions. Binding to large heparan sulfate proteoglycan structures promotes oligomerization. Binding to chondroitin sulfate proteoglycan does not lead to oligomerization. Interacts (via Ig-like domains) with NTRK3. Interacts (via Ig-like domains) with NTRK1, but does not form detectable complexes with NTRK2. Interacts with PPFIA1, PPFIA2 and PPFIA3.

Subcellular location. Cell membrane. Cell projection. Axon. Perikaryon. Cytoplasmic vesicle. Secretory vesicle. Synaptic vesicle membrane. Synapse. Synaptosome. Postsynaptic density. Neuron projection. Growth cone.

Tissue specificity. Detected in peripheral blood plasmacytoid dendritic cells (at protein level). Detected in all tissues tested except for placenta and liver. Detected in peripheral blood plasmacytoid dendritic cells.

Post-translational modifications. A cleavage occurs, separating the extracellular domain from the transmembrane segment. This process called ’ectodomain shedding’ is thought to be involved in receptor desensitization, signal transduction and/or membrane localization.

Similarity. Belongs to the protein-tyrosine phosphatase family. Receptor class 2A subfamily.

Isoforms (7)

UniProt ID	Names	Canonical?
Q13332-1	1, PTPS	yes
Q13332-2	PTPS-MEA
Q13332-3	PTPS-MEB
Q13332-4	PTPS-MEC
Q13332-5	PTPS-F4-7
Q13332-6	2
Q13332-7	3

RefSeq proteins (7): NP_001380940, NP_001380941, NP_001380942, NP_002841, NP_570923, NP_570924, NP_570925 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR016130	Tyr_Pase_AS	Active_site
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050713	RTP_Phos/Ushers	Family

Pfam: PF00041, PF00102, PF07679, PF13927

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (177 total): strand 75, helix 27, domain 13, sequence conflict 13, turn 12, splice variant 7, glycosylation site 4, mutagenesis site 4, region of interest 3, compositionally biased region 3, binding site 3, disulfide bond 3, topological domain 2, active site 2, sequence variant 2, signal peptide 1, chain 1, site 1, transmembrane region 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
2FH7	X-RAY DIFFRACTION	2
4BPC	X-RAY DIFFRACTION	2.1
2YD3	X-RAY DIFFRACTION	2.3
2YD2	X-RAY DIFFRACTION	2.55
2YD9	X-RAY DIFFRACTION	2.6
4PBX	X-RAY DIFFRACTION	3.15

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13332-F1	81.94	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 1589 (phosphocysteine intermediate); 1880 (phosphocysteine intermediate); 1197–1198 (cleavage)

Ligand- & substrate-binding residues (3): 1557; 1589–1595; 1633

Disulfide bonds (3): 54–107, 156–216, 266–311

Glycosylation sites (4): 263, 308, 733, 940

Mutagenesis-validated functional residues (4):

Position	Phenotype
97	abolishes interaction with ntrk3; when associated with a-100.
100	abolishes interaction with ntrk3; when associated with a-97.
233	abolishes interaction with ntrk3.
241–242	decreases interaction with ntrk3.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-3000178	ECM proteoglycans
R-HSA-388844	Receptor-type tyrosine-protein phosphatases
R-HSA-8849932	Synaptic adhesion-like molecules
R-HSA-9034015	Signaling by NTRK3 (TRKC)

MSigDB gene sets: 394 (showing top): GOBP_SPINAL_CORD_DEVELOPMENT, GOBP_DENDRITE_DEVELOPMENT, GOBP_ENDOTHELIAL_CELL_DEVELOPMENT, GOBP_HINDBRAIN_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_DENDRITIC_SPINE_DEVELOPMENT, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_REGULATION_OF_COLLATERAL_SPROUTING, GOBP_METENCEPHALON_DEVELOPMENT, GOBP_NEURON_PROJECTION_EXTENSION, GOBP_NEGATIVE_REGULATION_OF_AXON_EXTENSION, GOBP_SYNAPSE_ASSEMBLY, GOBP_EPITHELIAL_CELL_DEVELOPMENT, GOBP_ESTABLISHMENT_OF_ENDOTHELIAL_INTESTINAL_BARRIER, GOBP_TOLL_LIKE_RECEPTOR_9_SIGNALING_PATHWAY

GO Biological Process (24): protein dephosphorylation (GO:0006470), signal transduction (GO:0007165), negative regulation of neuron projection development (GO:0010977), spinal cord development (GO:0021510), cerebellum development (GO:0021549), hippocampus development (GO:0021766), cerebral cortex development (GO:0021987), corpus callosum development (GO:0022038), negative regulation of axon extension (GO:0030517), negative regulation of interferon-alpha production (GO:0032687), negative regulation of interferon-beta production (GO:0032688), negative regulation of toll-like receptor 9 signaling pathway (GO:0034164), peptidyl-tyrosine dephosphorylation (GO:0035335), negative regulation of collateral sprouting (GO:0048671), negative regulation of axon regeneration (GO:0048681), modulation of chemical synaptic transmission (GO:0050804), negative regulation of dendritic spine development (GO:0061000), establishment of endothelial intestinal barrier (GO:0090557), regulation of postsynaptic density assembly (GO:0099151), trans-synaptic signaling (GO:0099537), synaptic membrane adhesion (GO:0099560), cell adhesion (GO:0007155), dephosphorylation (GO:0016311), synapse organization (GO:0050808)

GO Molecular Function (7): phosphoprotein phosphatase activity (GO:0004721), protein tyrosine phosphatase activity (GO:0004725), heparin binding (GO:0008201), chondroitin sulfate binding (GO:0035374), heparan sulfate proteoglycan binding (GO:0043395), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (17): cytosol (GO:0005829), plasma membrane (GO:0005886), axon (GO:0030424), growth cone (GO:0030426), synaptic vesicle membrane (GO:0030672), presynaptic membrane (GO:0042734), perikaryon (GO:0043204), extracellular exosome (GO:0070062), Schaffer collateral - CA1 synapse (GO:0098685), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), postsynaptic density (GO:0014069), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995), neuron projection (GO:0043005), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Protein-protein interactions at synapses	2
Extracellular matrix organization	1
Signaling by NTRKs	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
anatomical structure development	5
cellular anatomical structure	4
pallium development	2
negative regulation of cell growth	2
negative regulation of developmental growth	2
negative regulation of axonogenesis	2
negative regulation of type I interferon production	2
glycosaminoglycan binding	2
sulfur compound binding	2
cytoplasm	2
synapse	2
dephosphorylation	1
protein modification process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of neuron projection development	1
neuron projection development	1
negative regulation of cell projection organization	1
central nervous system development	1
metencephalon development	1
limbic system development	1
telencephalon development	1
regulation of axon extension	1
axon extension	1
interferon-alpha production	1
regulation of interferon-alpha production	1
interferon-beta production	1
regulation of interferon-beta production	1
toll-like receptor 9 signaling pathway	1
regulation of toll-like receptor 9 signaling pathway	1
negative regulation of cytoplasmic pattern recognition receptor signaling pathway	1
protein dephosphorylation	1
collateral sprouting	1
regulation of collateral sprouting	1
axon regeneration	1
negative regulation of response to external stimulus	1
regulation of axon regeneration	1

Protein interactions and networks

STRING

1700 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRS	LRRC4B	Q9NT99	978
PTPRS	NTRK3	Q16288	971
PTPRS	PPFIA1	Q13136	945
PTPRS	IL1RAP	Q9NPH3	921
PTPRS	SLITRK1	Q96PX8	914
PTPRS	IL1RAPL1	Q9NZN1	874
PTPRS	AGRN	O00468	863
PTPRS	ZNRF4	Q8WWF5	854
PTPRS	LRRTM4	Q86VH4	853
PTPRS	PTS	Q03393	850
PTPRS	LRFN4	Q6PJG9	816
PTPRS	GPC1	P35052	812
PTPRS	RTN4RL1	Q86UN2	812
PTPRS	PPFIBP1	Q86W92	737
PTPRS	NRXN1	Q9ULB1	732

IntAct

172 interactions, top by confidence:

A	B	Type	Score
STX11	SNAP23	psi-mi:“MI:0914”(association)	0.900
NTRK3	PTPRS	psi-mi:“MI:0915”(physical association)	0.670
TNFSF8	TOR1B	psi-mi:“MI:0914”(association)	0.640
PDGFRB	PIK3R2	psi-mi:“MI:0914”(association)	0.610
IL1RAP	PTPRS	psi-mi:“MI:0915”(physical association)	0.540
IL1RAPL1	PTPRS	psi-mi:“MI:0915”(physical association)	0.540
PTPRS	IL1RAPL2	psi-mi:“MI:0915”(physical association)	0.540
LRFN4	PTPRS	psi-mi:“MI:0915”(physical association)	0.540
IL1RAPL2	PTPRS	psi-mi:“MI:0915”(physical association)	0.540
LRFN1	PTPRS	psi-mi:“MI:0915”(physical association)	0.540
PTPRS	LRFN5	psi-mi:“MI:0915”(physical association)	0.540
LRFN1	PTPRS	psi-mi:“MI:0407”(direct interaction)	0.540
LRFN4	PTPRS	psi-mi:“MI:0407”(direct interaction)	0.540
PTPRS	LRFN5	psi-mi:“MI:0407”(direct interaction)	0.540
IL1RAPL1	PTPRS	psi-mi:“MI:0407”(direct interaction)	0.540
IL1RAPL2	PTPRS	psi-mi:“MI:0407”(direct interaction)	0.540
PTPRS	IL1RAP	psi-mi:“MI:0407”(direct interaction)	0.540
ARRDC4	WWP2	psi-mi:“MI:0914”(association)	0.530
SLC39A5	TMEM223	psi-mi:“MI:0914”(association)	0.530
KLRG2	GXYLT2	psi-mi:“MI:0914”(association)	0.530
HLA-DPA1	TYW5	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
MANSC1	KLRG2	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
PCDHGB1	FAM171A2	psi-mi:“MI:0914”(association)	0.530
CRP	QSOX1	psi-mi:“MI:0914”(association)	0.530

BioGRID (199): PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), PTPRS (Affinity Capture-MS), TRIO (Proximity Label-MS), PPFIA1 (Proximity Label-MS), PTPRF (Proximity Label-MS), CASKIN2 (Proximity Label-MS), PTPRS (Affinity Capture-MS)

ESM2 similar proteins: A2A8L5, A4IFW2, A7MBJ4, B0V2N1, F1NWE3, O00533, O42414, O55005, O89026, O94856, O97394, P10586, P11627, P16621, P22063, P23468, P28685, P32004, P70232, P97685, P97686, Q02246, Q05695, Q13332, Q28902, Q2EY14, Q2EY15, Q2VWP7, Q2VWP9, Q3UH53, Q589G5, Q58EX2, Q61330, Q64487, Q64604, Q64605, Q6V4S5, Q7Z5N4, Q810U3, Q810U4

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
HSPG2	up-regulates	PTPRS	binding
LRFN5	“up-regulates activity”	PTPRS	binding
PTPRS	up-regulates	Synaptic_plasticity
PTPRS	“down-regulates activity”	EGFR	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 198 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Receptor-type tyrosine-protein phosphatases	5	21.6×	1e-03
Synaptic adhesion-like molecules	5	20.6×	1e-03
Protein-protein interactions at synapses	6	12.1×	1e-03
Constitutive Signaling by Aberrant PI3K in Cancer	8	7.7×	1e-03
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	9	6.6×	1e-03
Neuronal System	12	4.0×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of postsynaptic density assembly	5	25.5×	4e-04
synaptic membrane adhesion	7	23.4×	2e-05
regulation of presynapse assembly	7	21.9×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

463 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	311
Likely benign	75
Benign	25

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
638621	NM_002850.4(PTPRS):c.4756G>A (p.Val1586Met)	Likely pathogenic

SpliceAI

6517 predictions. Top by Δscore:

Variant	Effect	Δscore
19:5207918:TTA:T	donor_loss	1.0000
19:5207919:TACCT:T	donor_loss	1.0000
19:5207920:A:AC	donor_gain	1.0000
19:5207920:A:T	donor_loss	1.0000
19:5207921:C:CA	donor_loss	1.0000
19:5207921:C:CC	donor_gain	1.0000
19:5207921:CCT:C	donor_gain	1.0000
19:5208053:CGGCA:C	acceptor_gain	1.0000
19:5208055:GCA:G	acceptor_gain	1.0000
19:5208056:CA:C	acceptor_gain	1.0000
19:5208056:CAC:C	acceptor_gain	1.0000
19:5208057:ACTGG:A	acceptor_loss	1.0000
19:5208058:C:CA	acceptor_loss	1.0000
19:5208058:C:CC	acceptor_gain	1.0000
19:5208065:C:CT	acceptor_gain	1.0000
19:5208066:A:T	acceptor_gain	1.0000
19:5208067:G:GC	acceptor_gain	1.0000
19:5208231:GCTCA:G	donor_loss	1.0000
19:5208232:CTCAC:C	donor_loss	1.0000
19:5208233:TCA:T	donor_loss	1.0000
19:5208234:CACCT:C	donor_loss	1.0000
19:5208236:C:A	donor_loss	1.0000
19:5208236:CCTG:C	donor_gain	1.0000
19:5208387:CCATC:C	acceptor_gain	1.0000
19:5208388:CATCC:C	acceptor_gain	1.0000
19:5208390:TC:T	acceptor_gain	1.0000
19:5208391:CC:C	acceptor_gain	1.0000
19:5208391:CCT:C	acceptor_loss	1.0000
19:5208392:C:CC	acceptor_gain	1.0000
19:5208392:CTAGA:C	acceptor_loss	1.0000

AlphaMissense

9862 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:5208349:A:G	W1844R	1.000
19:5208349:A:T	W1844R	1.000
19:5210482:A:T	V1825D	1.000
19:5210488:A:G	F1823S	1.000
19:5210576:A:G	W1794R	1.000
19:5210576:A:T	W1794R	1.000
19:5210747:A:G	W1765R	1.000
19:5210747:A:T	W1765R	1.000
19:5212443:A:G	W1555R	1.000
19:5212443:A:T	W1555R	1.000
19:5212451:A:G	F1552S	1.000
19:5219341:A:G	C1298R	1.000
19:5219346:A:T	I1296K	1.000
19:5219453:A:C	S1260R	1.000
19:5219453:A:T	S1260R	1.000
19:5219455:T:G	S1260R	1.000
19:5221165:A:G	F1097S	1.000
19:5222164:A:G	W1054R	1.000
19:5222164:A:T	W1054R	1.000
19:5222175:A:T	V1050D	1.000
19:5243942:C:T	G510E	1.000
19:5243943:C:A	G510W	1.000
19:5243943:C:G	G510R	1.000
19:5243943:C:T	G510R	1.000
19:5243959:G:C	F504L	1.000
19:5243959:G:T	F504L	1.000
19:5243961:A:G	F504L	1.000
19:5243966:A:G	L502P	1.000
19:5244048:A:G	W475R	1.000
19:5244048:A:T	W475R	1.000

dbSNP variants (sampled 300 via entrez): RS1000017169 (19:5302590 A>G), RS1000020878 (19:5216690 A>T), RS1000026082 (19:5226145 G>A), RS1000030687 (19:5308903 G>A,C), RS1000036264 (19:5337028 C>T), RS1000087332 (19:5214824 C>G), RS1000093372 (19:5332275 G>A), RS1000102828 (19:5338474 G>A,T), RS1000124890 (19:5264559 C>T), RS1000136883 (19:5296946 G>A), RS1000142032 (19:5222008 TCTGA>T), RS1000156133 (19:5247919 G>A,C), RS1000160858 (19:5209546 T>A), RS1000180575 (19:5311140 A>G), RS1000183650 (19:5272985 T>C)

Disease associations

OMIM: gene MIM:601576 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): hearing loss disorder (MONDO:0005365), NK-cell enteropathy (MONDO:0016996)

Orphanet (1): NK-cell enteropathy (Orphanet:263665)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST008155_5	Waist-hip ratio	6.000000e-06
GCST009379_228	Type 2 diabetes	6.000000e-06
GCST010653_95	Thyroid stimulating hormone levels	2.000000e-13

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004343	waist-hip ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2396508 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 8,592 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL8260	BAICALEIN	2	8,592

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Receptor tyrosine phosphatase (RTP) family

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
compound 7b [Haftchenary et al., 2013]	Inhibition	5.44	pIC50
7-BIA	Inhibition	4.4	pIC50

ChEMBL bioactivities

25 potent at pChembl≥5 of 33 total, top 24 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.30	IC50	500	nM	IRIGENOL
6.22	IC50	600	nM	CHEMBL3633138
6.22	IC50	600	nM	SCUTELLAREIN
6.10	IC50	800	nM	CHEMBL3739950
6.05	IC50	900	nM	CHEMBL3633139
6.05	IC50	900	nM	CHEMBL3740878
5.52	IC50	3000	nM	CHEMBL398328
5.44	IC50	3600	nM	CHEMBL1829872
5.37	IC50	4300	nM	CHEMBL1829864
5.37	IC50	4300	nM	MORIN
5.35	IC50	4500	nM	CHEMBL4469905
5.34	IC50	4600	nM	CHEMBL3218925
5.28	IC50	5200	nM	CHEMBL1829871
5.27	IC50	5400	nM	CHEMBL3740356
5.21	IC50	6100	nM	CHEMBL3218926
5.20	IC50	6300	nM	CHEMBL2023985
5.18	IC50	6600	nM	CHEMBL3739990
5.12	IC50	7500	nM	CHEMBL4449755
5.11	IC50	7700	nM	CHEMBL5421141
5.10	IC50	7900	nM	CHEMBL3632914
5.08	IC50	8300	nM	SODIUM ORTHOVANAD
5.08	IC50	8400	nM	CHEMBL4447474
5.07	IC50	8600	nM	CHEMBL3319356
5.00	IC50	1e+04	nM	SODIUM ORTHOVANAD

PubChem BioAssay actives

17 with measured affinity, of 97 total; 17 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5,6,7-trihydroxy-3-(3,4,5-trihydroxyphenyl)chromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	0.5000	uM
4-[5-[4-[[[2-[4-carboxy-N-[(4-cyclohexylphenyl)methyl]-3-hydroxyanilino]-2-oxoethyl]-quinolin-8-ylsulfonylamino]methyl]triazol-1-yl]pentanoylamino]-2-hydroxybenzoic acid	1255198: Inhibition of GST-tagged PTP-sigma (unknown origin) by plate reader analysis using DiFMUP as substrate	ic50	0.6000	uM
5,6,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	0.6000	uM
2-(furan-2-yl)-5,6,7-trihydroxychromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	0.8000	uM
4-[6-[4-[[[2-[4-carboxy-N-[(4-cyclohexylphenyl)methyl]-3-hydroxyanilino]-2-oxoethyl]-quinolin-8-ylsulfonylamino]methyl]triazol-1-yl]hexanoylamino]-2-hydroxybenzoic acid	1255198: Inhibition of GST-tagged PTP-sigma (unknown origin) by plate reader analysis using DiFMUP as substrate	ic50	0.9000	uM
2-(furan-3-yl)-5,6,7-trihydroxychromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	0.9000	uM
7-hydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	3.0000	uM
2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	4.3000	uM
4-[(4-cyclohexylphenyl)methyl-[2-[methyl(quinolin-8-ylsulfonyl)amino]acetyl]amino]-2-hydroxybenzoic acid	1255198: Inhibition of GST-tagged PTP-sigma (unknown origin) by plate reader analysis using DiFMUP as substrate	ic50	4.3000	uM
(1R,3S,4R,7S,10S,11S,13R,15S,16R,17R,24R,25R,31S)-24-hydroxy-4,6,7,9,13,15-hexamethyl-18,26-dioxa-28-azaoctacyclo[22.2.2.219,22.13,10.01,25.04,8.011,16.017,31]hentriaconta-5,8,19(30),20,22(29)-pentaene-2,27-dione	2035209: Inhibition of human PTPsigma	ic50	4.5000	uM
5,6,7-trihydroxy-2-thiophen-3-ylchromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	5.4000	uM
5,7-dihydroxy-6-methoxy-2-(4-phenylphenyl)chromen-4-one	1265972: Inhibition of recombinant human PTP-sigma (residues 1367 to 1948) using para-nitrophenylphosphate as substrate for 60 mins by fluorescence analysis	ic50	6.6000	uM
(3R,4R,5S,7R,9S,10S,13S,16R,17R,19R,23S,30S)-5,7,11,13,14,16-hexamethyl-2-oxa-21-azaheptacyclo[23.2.2.13,10.04,9.012,16.019,23.017,30]triaconta-1(28),11,14,25(29),26-pentaene-18,20,22-trione	2035209: Inhibition of human PTPsigma	ic50	7.5000	uM
(3R,4R,5S,7R,9S,10S,13S,16R,17S,19R,23S,30S)-5,7,11,13,14,16-hexamethyl-2-oxa-21-azaheptacyclo[23.2.2.13,10.04,9.012,16.019,23.017,30]triaconta-1(28),11,14,25(29),26-pentaene-18,20,22-trione	2035209: Inhibition of human PTPsigma	ic50	7.7000	uM
4-[4-[4-[[[2-[4-carboxy-N-[(4-cyclohexylphenyl)methyl]-3-hydroxyanilino]-2-oxoethyl]-quinolin-8-ylsulfonylamino]methyl]triazol-1-yl]butanoylamino]-2-hydroxybenzoic acid	1255198: Inhibition of GST-tagged PTP-sigma (unknown origin) by plate reader analysis using DiFMUP as substrate	ic50	7.9000	uM
(3S,4R,5S,7R,9S,10S,13S,16R,17R,22R,30S)-22-hydroxy-5,7,11,13,14,16-hexamethyl-2-oxa-21-azaheptacyclo[22.2.2.13,10.119,22.04,9.012,16.017,30]triaconta-1(27),11,14,19(29),24(28),25-hexaene-18,20-dione	2035209: Inhibition of human PTPsigma	ic50	8.4000	uM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	1182555: Inhibition of PTPsigma (unknown origin)	ic50	8.6000	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases expression, increases methylation	4
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression, affects expression	3
trichostatin A	affects cotreatment, decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Arsenic	affects cotreatment, decreases expression, increases abundance, affects methylation	2
Benzo(a)pyrene	affects methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tretinoin	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
bisphenol A	increases methylation, decreases methylation, affects cotreatment	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
bisphenol S	decreases methylation	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	decreases expression	1
Glyphosate	increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects expression	1
Manganese	decreases expression, increases abundance, affects cotreatment	1
Methylnitronitrosoguanidine	decreases expression	1

ChEMBL screening assays

17 unique, capped per target: 17 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2401186	Binding	Inhibition of recombinant PTPsigma (unknown origin) using pNPP as substrate at 100 uM by spectrophotometric analysis	A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. — J Med Chem

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2CT	Abcam HeLa PTPRS KO	Cancer cell line	Female
CVCL_TH72	HAP1 PTPRS (-) 1	Cancer cell line	Male
CVCL_TH73	HAP1 PTPRS (-) 2	Cancer cell line	Male
CVCL_TH74	HAP1 PTPRS (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
NCT01109576	EARLY_PHASE1	COMPLETED	Workshops for Veterans With Vision and Hearing Loss